Sunshine Biopharma, Inc. (NASDAQ:SBFM) Stock Short Interest Report for October

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 840,899 shares, an increase of 539.6% from the September 30th total of 131,478 shares. Currently, 19.8% of the company’s stock are short sold. Based on an average daily volume of 28,786,521 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SBFM shares. Wall Street Zen raised Sunshine Biopharma to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings downgraded Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, October 13th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce”.

Sunshine Biopharma Trading Up 5.1%

Shares of SBFM traded up $0.15 during trading hours on Wednesday, reaching $3.11. 225,823 shares of the stock traded hands, compared to its average volume of 116,316. The stock has a fifty day simple moving average of $15.35 and a 200 day simple moving average of $113.27. Sunshine Biopharma has a 52 week low of $2.58 and a 52 week high of $464.00. The company has a market cap of $671,760.00, a price-to-earnings ratio of -0.02 and a beta of 1.20.

Sunshine Biopharma (NASDAQ:SBFM) last released its quarterly earnings results on Thursday, August 13th. The company reported ($23.00) earnings per share for the quarter, topping the consensus estimate of ($24.00) by $1.00. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. The business had revenue of $9.26 million for the quarter, compared to analysts’ expectations of $8.70 million. Analysts predict that Sunshine Biopharma will post -39.00 earnings per share for the current fiscal year.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.

In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.